Sun Pharmaceutical Industries Limited (SUNPHARMA)

Outcome of the 34th Annual General Meeting held on 31 July 2026

Filed: 31 Jul 2026, 20:34 IST Exchange: BSE Category: General Update — Shareholder Meeting Outcome

Outcome of 34th Annual General Meeting held on 31 July 2026 - All resolutions including financial statements adoption and dividend declaration approved - Re-appointment and remuneration revision of Mr. Aalok Shanghvi approved - Appointment of Dr. Andreas Busch as Independent Director approved - Chairman Dilip Shanghvi delivered speech highlighting FY26 performance and strategic priorities - Shareholders engaged via e-voting and Q&A session with Managing Director - Meeting conducted via video conferencing in compliance with regulations

Source: Original filing PDF — view on exchange portal

⚡ You're reading this after the fact — subscribers got it instantly

ISA

Indian Stock Alerts BOT

🚨 SUNPHARMA — Quarterly Results

Revenue: ₹2,35,800 Cr (+12% YoY)

PAT: ₹19,200 Cr (+17% YoY)

EBITDA margin: 16.8%

Board declared ₹10/share dividend. Jio adds 8M subs.

📎 bseindia.com/xml-data/...

🎧 Audio summary ready

✓✓ 6:47 PM

🎧

Instant audio summaries2-min AI concall recap delivered with every earnings alert

📊

20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings

🔍

Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically

⚡

Instant Telegram alertsResults, board meetings, insider trades — within minutes

Add SUNPHARMA to your watchlist — all of this, automated.

14-day Pro trial · No credit card · Cancel anytime

More on Sun Pharmaceutical Industries Limited

Important. The summary above is generated automatically from Sun Pharmaceutical Industries Limited's own public regulatory filing under SEBI LODR. Indian Stock Alerts is not a SEBI-registered Research Analyst or Investment Adviser. This page is informational, not investment advice, a recommendation to buy or sell any security, or any opinion about the company's business, governance or financial health. Always read the original filing before acting and consult a registered adviser for investment decisions.